The Global Bioresorbable Coronary Stents Market was valued at USD 550.09 million in 2024 and is projected to witness substantial growth during the forecast period, registering a CAGR of 10.25% through 2030. Recent advancements in cardiology have significantly enhanced patient outcomes and quality of life for individuals suffering from coronary artery disease (CAD). Among these innovations, bioresorbable coronary stents have emerged as a transformative solution, marking a paradigm shift in CAD treatment. Unlike traditional metallic stents, these stents are designed to gradually dissolve within the body after fulfilling their function of arterial support.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 550.09 Million
Market Size 2030	USD 990.08 Million
CAGR 2025-2030	10.25%
Fastest Growing Segment	Hospitals & Clinics
Largest Market	North America

Market Drivers

Increasing Prevalence of Cardiovascular Diseases (CVDs)

The growing global incidence of cardiovascular diseases represents a key driver for market expansion. CVDs remain the leading cause of death globally, responsible for 17.9 million deaths in 2019-approximately 32% of global mortality. Notably, 85% of these fatalities were due to heart attacks and strokes. Furthermore, over 75% of CVD-related deaths occur in low- and middle-income countries, highlighting a critical gap in healthcare infrastructure and access to advanced cardiac care.

The rising number of patients diagnosed with coronary artery disease (CAD) has spurred demand for innovative treatment approaches like bioresorbable coronary stents. In 2022, the global prevalence of CAD was estimated at 315 million cases, with a 95% uncertainty range of 273 to 362 million. The age-standardized prevalence rate was recorded at 3,605 per 100,000 individuals, underscoring the widespread nature of the disease.

The aging global population is a significant contributing factor, as age is the most prominent non-modifiable risk factor for CAD and related cardiovascular conditions. According to the American Heart Association (AHA) 2019 update, 31% of men and 25.4% of women aged 80 and above are diagnosed with CAD. In addition, lifestyle factors such as hypertension, diabetes, obesity, and physical inactivity continue to escalate the global burden of cardiovascular risk, further supporting the shift toward bioresorbable stent adoption.

Market Challenges

Efficacy and Safety Concerns

Despite their promising potential, bioresorbable coronary stents face ongoing scrutiny regarding their clinical safety and efficacy. Some trials have raised concerns about the risk of stent thrombosis-the formation of blood clots within or near the stent-leading to potentially life-threatening complications. These concerns have prompted a comparative evaluation against conventional metallic stents, particularly in terms of long-term safety outcomes.

Market Trends

Technological Advancements

Rapid innovation in medical technology has significantly influenced the development and adoption of bioresorbable coronary stents. Continuous advancements in material science have enabled the creation of stents that maintain mechanical strength during initial healing phases while degrading safely thereafter. The use of biocompatible materials has improved both patient outcomes and procedural safety.

State-of-the-art manufacturing techniques such as 3D printing and laser cutting allow for the production of highly intricate stent designs, optimizing both radial strength and vascular conformability. Many stents are now developed with drug-eluting properties, enabling the controlled release of therapeutic agents to reduce risks of restenosis and inflammation.

Innovations in intravascular imaging technologies, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), have further enhanced procedural accuracy by providing high-resolution, real-time visualization of stent deployment. This precision supports optimal placement and expands the therapeutic potential of bioresorbable stents.

Ongoing clinical research and trials continue to refine stent designs and validate long-term outcomes, offering valuable data that guide next-generation product development and regulatory approvals.

Key Market Players

BIOTRONIK SE & Co. KG
Meril Life Sciences Pvt. Ltd
Elixir Medical Corporation.
Reva Medical, LLC
Terumo Corporation
Lepu Medical Technology (Beijing)Co.,Ltd
MicroPort Scientific Corporation
LifeTech Scientific Corporation
Boston Scientific Corporation
Medtronic plc

Report Scope:

In this report, the Global Bioresorbable Coronary Stents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bioresorbable Coronary Stents Market, By Brand:

Magmaris
Magnitude
MeRes-100
DESolve
Others

Bioresorbable Coronary Stents Market, By End User:

Hospitals & Clinics
Ambulatory Care Centers
Others

Bioresorbable Coronary Stents Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bioresorbable Coronary Stents Market.

Available Customizations:

Global Bioresorbable Coronary Stents market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Bioresorbable Coronary Stents Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Brand (Magmaris, Magnitude, MeRes-100, DESolve, Others)
- 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Bioresorbable Coronary Stents Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Brand
- 6.2.2. By End User
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Bioresorbable Coronary Stents Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Brand
    - 6.3.1.2.2. By End User
- 6.3.2. Canada Bioresorbable Coronary Stents Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Brand
    - 6.3.2.2.2. By End User
- 6.3.3. Mexico Bioresorbable Coronary Stents Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Brand
    - 6.3.3.2.2. By End User

7. Europe Bioresorbable Coronary Stents Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Brand
- 7.2.2. By End User
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Bioresorbable Coronary Stents Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Brand
    - 7.3.1.2.2. By End User
- 7.3.2. United Kingdom Bioresorbable Coronary Stents Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Brand
    - 7.3.2.2.2. By End User
- 7.3.3. Italy Bioresorbable Coronary Stents Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Brand
    - 7.3.3.2.2. By End User
- 7.3.4. France Bioresorbable Coronary Stents Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Brand
    - 7.3.4.2.2. By End User
- 7.3.5. Spain Bioresorbable Coronary Stents Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Brand
    - 7.3.5.2.2. By End User

8. Asia-Pacific Bioresorbable Coronary Stents Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Brand
- 8.2.2. By End User
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Bioresorbable Coronary Stents Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Brand
    - 8.3.1.2.2. By End User
- 8.3.2. India Bioresorbable Coronary Stents Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Brand
    - 8.3.2.2.2. By End User
- 8.3.3. Japan Bioresorbable Coronary Stents Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Brand
    - 8.3.3.2.2. By End User
- 8.3.4. South Korea Bioresorbable Coronary Stents Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Brand
    - 8.3.4.2.2. By End User
- 8.3.5. Australia Bioresorbable Coronary Stents Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Brand
    - 8.3.5.2.2. By End User

9. South America Bioresorbable Coronary Stents Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Brand
- 9.2.2. By End User
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Bioresorbable Coronary Stents Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Brand
    - 9.3.1.2.2. By End User
- 9.3.2. Argentina Bioresorbable Coronary Stents Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Brand
    - 9.3.2.2.2. By End User
- 9.3.3. Colombia Bioresorbable Coronary Stents Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Brand
    - 9.3.3.2.2. By End User

10. Middle East and Africa Bioresorbable Coronary Stents Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Brand
- 10.2.2. By End User
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Bioresorbable Coronary Stents Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Brand
    - 10.3.1.2.2. By End User
- 10.3.2. Saudi Arabia Bioresorbable Coronary Stents Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Brand
    - 10.3.2.2.2. By End User
- 10.3.3. UAE Bioresorbable Coronary Stents Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Brand
    - 10.3.3.2.2. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Bioresorbable Coronary Stents Market: SWOT Analysis

14. Competitive Landscape

14.1. BIOTRONIK SE & Co. KG
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
14.2. Meril Life Sciences Pvt. Ltd
14.3. Elixir Medical Corporation.
14.4. Reva Medical, LLC
14.5. Terumo Corporation
14.6. Lepu Medical Technology (Beijing)Co.,Ltd
14.7. MicroPort Scientific Corporation
14.8. LifeTech Scientific Corporation
14.9. Boston Scientific Corporation
14.10.Medtronic plc

15. Strategic Recommendations

16. About Us & Disclaimer

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION